#31
|
||||
|
||||
Àïäåéò ACCP ãàéäà ïî ÒÃÂ:
Chest. 2016 Feb;149(2):315-52. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. ïîëíûé òåêñò äîñòóïåí ïî êëèêó íà ñòðàíèöå [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#32
|
||||
|
||||
Ðîññèéñêèå ðåêîìåíäàöèè ïî ïðîôèëàêòèêå è ëå÷åíèþ âåíîçíûõ òðîìáîýìáîëè÷åñêèõ îñëîæíåíèé (ÂÒÝÎ) 2015
(âî âëîæåííîì ôàéëå)
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#33
|
||||
|
||||
Ðåêîìåíäàöèè ïî äèàãíîñòèêå è ëå÷åíèþ âàðèêîçà Ìèíçäðàâà ÐÔ, 2017: «[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]».
Ðàçðàáîòàíû ðàáî÷åé ãðóïïîé îò Àññîöèàöèè ôëåáîëîãîâ Ðîññèè.
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷ |
#34
|
||||
|
||||
Ñèñòåìàòè÷åñêèé îáçîð ïî òðîìáîçó âåí âåðõíèõ êîíå÷íîñòåé:
Deep Vein Thrombosis of the Upper Extremity A Systematic Review Dtsch Arztebl Int. 2017 Apr; 114(14): 244–249 [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#35
|
||||
|
||||
Cleve Clin J Med. 2017 Jul;84(7):545-554.
Optimizing diagnostic testing for venous thromboembolism. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#36
|
||||
|
||||
Íåêîòîðûå òîíêîñòè íàçíà÷åíèÿ àíòèêîàãóëÿíòîâ àòëåòàì/ñïîðòñìåíàì â íåäàâíåé ïóáëèêàöèè:
J Thromb Haemost. 2017 Jun;15(6):1051-1054. Athletes and blood clots: individualized, intermittent anticoagulation management. Berkowitz JN, Moll S. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#37
|
||||
|
||||
A primary-outcome event occurred in 67 of the 522 patients (12.8%) in the edoxaban group as compared with 71 of the 524 patients (13.5%) in the dalteparin group (hazard ratio, 0.97; 95% confidence interval [CI], 0.70 to 1.36; P=0.006 for noninferiority; P=0.87 for superiority). Recurrent venous thromboembolism occurred in 41 patients (7.9%) in the edoxaban group and in 59 patients (11.3%) in the dalteparin group (difference in risk, -3.4 percentage points; 95% CI, -7.0 to 0.2). Major bleeding occurred in 36 patients (6.9%) in the edoxaban group and in 21 patients (4.0%) in the dalteparin group (difference in risk, 2.9 percentage points; 95% CI, 0.1 to 5.6).
--- N Engl J Med. 2017 Dec 12. doi: 10.1056/NEJMoa1711948. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
|
#38
|
||||
|
||||
Blood Adv. 2018 Nov 13;2(21):3081-3087.
Who should get long-term anticoagulant therapy for venous thromboembolism and with what? [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |
#39
|
||||
|
||||
American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
__________________
Èñêðåííå, Âàäèì Âàëåðüåâè÷. |